A number of important questions remain unanswered with respect to early events that limit tumor growth and progression as a neoplasm begins to become deprived of oxygen and nutrients. As this occurs cells experience hypoxia and acidosis that lead to activation of a p53-dependent checkpoint. Little is known about the molecular events upstream of p53 during hypoxia-induced checkpoint activation and what are the mediators of hypoxia-induced tumor suppression. Our working hypothesis is that hypoxia activates checkpoints that limit early tumor expansion and that this involves p53 and its transcriptional target genes. In addition there are multiple survival pathways selected for during hypoxia including p53 mutation, HIF activation, alteration in Myc signaling or BRCA1-dependent repair that may impact on tumor growth and survival. We propose to explore these pathways through the following specific aims:
Aim 1 : Investigate hypoxia-induced apoptotic checkpoint. A. Elucidate markers, kinases. Modifications that regulate p53 in vitro and in vivo;perform colocalization between p53 and its checkpoint regulators with regions of hypoxia using immunohistochemistry and immunofluorescence. B. Investigate apoptotic targets and their localization during hypoxia;utilize microarrays, chromatin immunoprecipitation and mass-spectrometry for analysis and to perform subsequent validation. C. Investigate p53 target genes in early damage checkpoint comparing normoxia with hypoxia in tumor samples.
Aim 2 : Examine requirements in tumor suppression of p53 targets and other pathways modulated by hypoxia in vivo. A. Utilize gene silencing, imaging, immunostaining and mouse xenografts to analyze the role of specific pro-apoptotic and growth inhibitory p53 target genes. B. Investigate cross-talk between p53, HIF, Myc and BRCA1 during hypoxia to unravel coordinated regulation in tumor suppression and deregulated function in cancer development. The proposed studies will provide insights into early events in tumor development with specific focus on hypoxia-induced checkpoints that must be suppressed. The work may lead to new strategies for limiting tumor growth at its earliest stages.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA123258-04
Application #
7674603
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Salnikow, Konstantin
Project Start
2006-08-04
Project End
2010-02-28
Budget Start
2009-08-01
Budget End
2010-02-28
Support Year
4
Fiscal Year
2009
Total Cost
$267,266
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Warfel, Noel A; Dolloff, Nathan G; Dicker, David T et al. (2013) CDK1 stabilizes HIF-1? via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle 12:3689-701
Dolloff, Nathan G; Allen, Joshua E; Dicker, David T et al. (2012) Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther 11:2321-30
Cazanave, Sophie C; Mott, Justin L; Bronk, Steven F et al. (2011) Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem 286:39336-48
Mayes, Patrick A; Dolloff, Nathan G; Daniel, Colin J et al. (2011) Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3? and CDK1. Cancer Res 71:5265-75
Dolloff, Nathan G; Mayes, Patrick A; Hart, Lori S et al. (2011) Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 3:86ra50
Navaraj, Arunasalam; Finnberg, Niklas; Dicker, David T et al. (2009) Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol Ther 8:2417-44
Allen, Joshua E; Hart, Lori S; Dicker, David T et al. (2009) Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther 8:2194-205
Matthew, Elizabeth M; Hart, Lori S; Astrinidis, Aristotelis et al. (2009) The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 8:4168-75
Lu, Chao; Wang, Wenge; El-Deiry, Wafik S (2008) Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther 7:2039-46
Tavaluc, Raluca T; Hart, Lori S; Dicker, David T et al. (2007) Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 6:2554-62

Showing the most recent 10 out of 12 publications